Amyloid and deoxyglucose PET Imaging in Alzheimer’s Disease and Vascular Cognitive Impairment patients with significant White Matter Disease

SE Black MD FRCP(C)
Brill Professor of Neurology
Sunnybrook HSC, U of Toronto
on behalf of the
MITNEC-C6 project group
Disclosure of Potential Conflict of Interest

Clinical Trial Contract Research:
Pfizer, Novartis, Roche, Lundbeck, Lilly-Avid, GE Healthcare,

CME Lecturer: Novartis, Eisai

Ad hoc Consultant: GE Healthcare, Lilly-Avid, Boehringer Ingelheim

No stock or equity interests
Medical Imaging Trials NEtwork of Canada (MITNEC) CIHR-funded network

- A national medical imaging clinical trials network established to provide a clinical platform for imaging research in Canada to move innovations in imaging to facilitate the uptake of research outcomes into clinical practice and improved patient care.
- Theme A – Imaging Trials in Oncology
- Theme B – Imaging Trials in Cardiology
- Theme C – Imaging Trials in Neurology
- Theme D - Clinical validation of non-reactor-based source of 99mTc

http://www.mitnec.org/
Rationale

- Small vessel disease often coexists with Alzheimer’s disease (AD) and can contribute to cognitive decline and progression to dementia.
- Longitudinal imaging using cerebral amyloid labeling is needed to understand the additive/interactive effects of small vessel disease and AD.
- Elders with extensive periventricular White Matter Disease may represent an at-risk group for amyloid deposition and could be an important target group for dementia prevention.
- Progression to dementia could be averted in at-risk groups through aggressive vascular risk factor management and potentially anti-amyloid agents.
Axis of pathological heterogeneity

- PCA
- vpAD
- IvAD
- fvAD
- ApoE e4
- typical AD
- tvAD
- Lewy bodies
- Age of Onset
- LOAD
- WMH
- EAOD
- Co-Pathology

Lam Alz Res Therapy 2013
SEBlack SHSC UofT
Demented

In Autopsy Series Dementia is usually a Co-morbid disease, especially with vascular lesions.

Not demented

Schneider et al Neurology 2007
Prevalence of amyloid positivity in Subcortical VaD

- Thirty-one (68.9%) of 45 patients with SVaD were negative for cortical PiB binding

- Significant differences between PiB-positive and PiB-negative groups in:
  - Age: older (79.5 vs 71.9 years)
  - MMSE: lower (18.6 vs 22.6)
  - Number of lacunes: fewer (3.9 vs 9.0)
  - Visual rating scale: more hippocampal atrophy (3.1 vs 2.3)

- PiB-negative SVaD performed better on delayed recall of both verbal and visual memory tests than the PiB-positive
Prevalence of amyloid positivity in Subcortical Vascular Dementia

- Thirty-one (31%) with SVaD had cortical PiB binding
- Significant differences between PiB-positive and PiB-negative groups in:
  - Age (79.5 vs 71.9 years)
  - Mini-Mental State Examination score (18.6 vs 22.6)
  - Number of lacunes (3.9 vs 9.0)
  - Visual rating scale of hippocampal atrophy (3.1 vs 2.3)
- PiB-negative SVaD patients performed better on delayed recall of both the verbal and visual memory test than PiB-positive patients

Lee et al Neurology 2011
AD and Control Perfusion Maps

(a) Alzheimer’s Disease

(b) Controls
Watershed Areas, Perfusion and Group Comparison

SEBlack SHSC UofT

Makedonov, EJN, 2013
Medullary veins

Penetrating arteries

SEBlack SHSC UofT

Okudera et al, Neuropathology 1999
Severely disturbed cortical vascular network in AD

Suter Stroke 2002
Periventricular White Matter Hyperintensities: A Venous Insufficiency Syndrome?

Stenosis of large and medium venules are the pathological correlate of PvWMH.

Courtesy of FQ Gao
Mechanisms for elimination of Aβ from the brain

- Neprilysin and Insulin Degrading Enzyme in Brain Parenchyma
- Degradation of Aβ by Microglia and Astrocytes
- Perivascular (Lymphatic) Drainage of Interstitial Fluid and Solute including Aβ
- Absorption into blood via Low density lipoprotein receptor-related protein-1 (LRP1) and P-glycoprotein mediated mechanisms

? CSF pathways

SEBlack SHSC UofT
Courtesy R Weller
Perivascular (lymphatic) drainage of interstitial fluid and solutes along basement membranes of capillaries and arteries.
CSF Tracer Influx into the Brain Parenchyma in WT Controls vs. $Aqp4$-null Mice

Ex vivo imaging

OA-647

$E$ Wild type $Aqp4^{-/-}$

t = 30 min

$F$ Tracer influx

Mean fluorescence intensity

<table>
<thead>
<tr>
<th></th>
<th>30 min</th>
<th>3 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$Aqp4^{-/-}$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Aim

• To determine in patients with significant WMD, stratified by apolipoprotein E e4 status:
  – The baseline prevalence and degree of uptake of amyloid on PET in relation to baseline clinical and multimodal brain imaging measures
  – if baseline white matter disease volume predicts increased amyloid uptake at 1 year

• To evaluate changes, if any, in amyloid uptake in correlation with the changes in clinical and structural and functional brain measures over 1 year
Primary Hypotheses

Patients who have high burden of Periventricular White Matter Hyperintensities (pvWMH) will have a higher likelihood of amyloid positive scans.

The volume of pvWMH will correlate with the standardized measures of florbetapir uptake.

Patients who have high burden of pvWMH volumes will show greater increase in amyloid deposition over one year.
Secondary Hypotheses

Patients with abnormal florbetapir uptake ratios on PET at baseline will have lower cognitive scores, hippocampal and brain volumes, and posterior cingulate-parietal–temporal metabolism on 18-FDG PET, and larger ventricular volumes compared to their subgroup counterparts with amyloid negative PET scans.

Baseline positive scans for florbetapir uptake will predict greater cognitive and functional decline at 1 year.
Research Design

• 120 patients (60 from stroke prevention clinics, 60 from memory clinics)
• 250 NC, 400 MCI, and 150 AD from ADNI-GO and ADNI-2 studies will serve as control groups
• Recruitment period: 9 months

• Study Procedures at baseline and one year
  • 3T-MRI
    (3DT1/PD/T2/FLAIR/GrEcho/DTI/rsFMRI/(ASL)
  • FDG-PET, Florbetapir Amyloid PET
  • Neuropsychological Testing
  • Blood sampling at baseline for APOE e4, BDNF, other genomics and metabolomics
Inclusion Criteria

• Age ≥ 60 years
• WMD score on CT or MRI of 3 on the Fazekas scale, but no cortical infarcts or subcortical >1cm
• Memory clinic patients will meet criteria for amnestic or multi-domain MCI and mild early AD (MMSE ≥ 20) using the same criteria as in the ADNI project
• TIA patients from stroke prevention clinics may have MMSE scores between 20 – 30
Exclusion Criteria

- Unsafe for 3T MRI
- Cortical or non-lacunar infarct
- Major psychiatric disorder during preceding 5 years
- History of substance abuse
- Serious/chronic systemic or neurological illness (other than Alzheimer’s disease)
Neuropsychology Protocol

• Mini Mental Status Exam (MMSE)
• Montreal Cognitive Assessment (MoCA)
• Phonemic and Semantic Fluency
• Trails A & B
• Symbol Digit Modalities Test
• The Centre for Epidemiologic Studies Depression scale (CES-D)

• To be added
  – ANART (American National Adult Reading Test)
  – TUG (Timed up and Go)
  – FAQ (Functional Assessment Questionnaire)
  – Other core neuropsychological tests from the ADNI battery
Example of Fazekas Scores

Fazekas 1

Fazekas 2

Fazekas 3
Fazekas 3

CT
Example of Fazekas 3 Scores

FLAIR

PD

T2

SEBlack SHSC UofT
Subjects and procedures

Study protocol

- 3T-MRI (structural, DTI, TF-MRI), FDG-PET, 18 florbetapir PET, Neuropsychological Testing, Blood Sampling (Apoe E e4) at baseline and at 12 months

- Analysis pipelines designed to derive total supratentorial intracranial volume, tissue segmentation including grey, white, lesion subtypes (lacunar, deep and periventricular hyperintensities), with adapted free surfer application
Lesion Explorer Segmentation

Summary of Outputs

T1 Segmentation

White matter hyperintensity seg

Final Segmentation Tissue Classes:
1. GM 2. WM 3. sCSF 4. vCSF 5. pvSH 6. dwSH 7. lacunes

Final Segmentation

Ramirez Neuroimage 2011
SEBlack SHSC UofT
Differences in mean cortical thickness (FreeSurfer alone vs FS+Lesion Explorer) for AD =168 vs NC =97

Color scale shows magnitude of difference from -0.3 mm (yellow) through 0.3 mm (red)

Zhao & Ramirez in prep

SEBlack SHSC UofT
Conclusions

1. The pathophysiology of AD is complex and still not fully understood though our ignorance is increasingly informed—oxidative stress, innate immunity, and poor clearance of amyloid all play a role in sporadic disease.

2. Heterogeneity of AD is important to recognize including co-morbidities, especially vascular.

3. Small Vessel Disease includes both disease arteriolar, capillary and venous mechanisms relevant to the pathophysiology of AD.
Research Team

Executive Committee
– Jean-Claude Tardiff
– Richard Frayne
– Frank Prato
– Eric Smith
– Stephen Strother
– John Valliant

Recruitment sites starting up in Toronto, Vancouver, London, Hamilton with 7 more planned
Acknowledgement of Financial Support

**Personal support**
- Brill Chair in Neurology; Brain Research, SRI, Dept of Med, SHSC, U of Toronto

**Peer-reviewed Funding**
- Canadian Institute of Health Research
- National Institutes of Health-ADNI
- Ontario Brain Institute

**Contract Research**
- Lilly-Avid: florbetapir

**Philanthropy:** L. C. Campbell, Slaight, Odette, Levy Foundations
HSF Centre for Stroke Recovery & LC Campbell Cognitive Neurology Research Unit

**Collaborators**
- Michael J. Bronskill
- Curtis Caldwell
- Anthony Feinstein
- David Gladstone
- Nathan Herrmann
- Krista Lanctot
- Brian Levine
- Nancy Lobaugh
- Mario Masellis
- William McIlroy
- Alan Moody
- Norman Park
- Eric Roy
- DJ Sahlas
- Richard Staines
- Gregory Stanisz
- Don Stuss

**Post-Doctoral Fellows**
- Benjamin Lam
- Jacqui Pettersen
- Kie Honjo
- Joel Ramirez

**Graduate Students**
- Joel Ramirez
- Graeme Schwindt
- Vessela Stamenova
- Alexandra Rowland

**Former Fellows/Students**
- Richard Swartz
- Sarah Duff Canning
- Jennifer Mandzia
- D. James Sahlas
- Aldofo Cotter
- Christian Bocchi
- BJ Tippett
- Peal Behl
- Naama Levy
- Neellesh Nadkami

**Research Associates**
- Fu Qiang Gao MD
- Farrell Leibovitch
- Jail Zhao

**Nurse Coordinator**
- Joanne Lawrence

**Research Coordinators**
- Jennifer Bray
- Anoop Ganda
- Robin Harris
- Isabel Lam
- Christopher Scott
- Alicia Mcneely
- Courtney Bereznuk